Last reviewed · How we verify
NCT06693986
Adenovirus (RGDCRAdCOX2F)
Phase 1 trial testing Replicative Adenovirus Vector (RGDCRAdCOX2F) in Adenocarcinoma of Pancreas in 18 participants. Currently enrolling.
15 October 2028
Quick facts
| Lead sponsor | Masonic Cancer Center, University of Minnesota |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 18 |
| Start date | 27 December 2024 |
| Primary completion | 15 October 2028 |
| Estimated completion | 15 October 2029 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Replicative Adenovirus Vector (RGDCRAdCOX2F) — full drug profile →
Conditions studied
- Adenocarcinoma of Pancreas — all drugs for Adenocarcinoma of Pancreas →
Sponsor
Masonic Cancer Center, University of Minnesota
Who can join
18 and older, any sex, with Adenocarcinoma of Pancreas. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single center, Phase I dose finding study of a single direct tumor injection of an RGD modified conditionally replicative adenovirus (RGDCRAdcox2F) in persons with adenocarcinoma of the pancreas. The study is designed to determine the MTD of RGDCRAdCOX2F that corresponds to the maximum desired toxicity of ≤ 20%.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting IL-12 for pancreatic cancer immunotherapy: advances in delivery strategies and clinical translation.
Schlatter J, Wei W, Chen Y, Melse A, et al · · 2026 · PMID 41958651 · DOI 10.3389/fimmu.2026.1755796 -
Current use of pre-clinical models for evaluation of human adenovirus-based cancer therapeutics.
Cole DK, Khanolkar RC, Davies JA, Gerry AB. · · 2026 · PMID 41647170 · DOI 10.1016/j.omton.2026.201130
Verify or expand the search:
- PubMed search for NCT06693986
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Masonic Cancer Center, University of Minnesota trials
Trials by the same sponsor.
- NCT06772090 — Probiotic Supplementation During Cytotoxic Chemotherapy for Solid Tumor Malignancies · NA · not yet recruiting
- NCT06584929 — Rural Smoking Cessation · NA · not yet recruiting
- NCT07153016 — LEgal Guidance and AdvocaCY for CAREgivers (LEGACY CARE): A Pilot Clinical Trial for Caregivers of Persons With Colorect · NA · recruiting
- NCT06792825 — HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL · Phase 2 · recruiting
- NCT07070726 — UNTOLD Ovarian Cancer Unmet Needs Survey · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06693986 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Masonic Cancer Center, University of Minnesota
- Last refreshed: 7 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06693986.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing